Alterations of pre-mRNA splicing in cancer.

Genes Chromosomes Cancer 2005 Apr;42(4):342-57

Biomedical Research and Study Centre, University of Latvia, Ratsupites St 1, LV-1067 Riga, Latvia.

Recent genomewide analyses of alternative splicing (AS) indicate that up to 70% of human genes may have alternative splice forms, suggesting that AS together with various posttranslational modifications plays a major role in the production of proteome complexity. Splice-site selection under normal physiological conditions is regulated in the developmental stage in a tissue type-specific manner by changing the concentrations and the activity of splicing regulatory proteins. Whereas spliceosomal errors resulting in the production of aberrant transcripts rarely occur in normal cells, they seem to be an intrinsic property of cancer cells. Changes in splice-site selection have been observed in various types of cancer and may affect genes implicated in tumor progression (for example, CD44, MDM2, and FHIT) and in susceptibility to cancer (for example, BRCA1 and APC). Splicing defects can arise from inherited or somatic mutations in cis-acting regulatory elements (splice donor, acceptor and branch sites, and exonic and intronic splicing enhancers and silencers) or variations in the composition, concentration, localization, and activity of regulatory proteins. This may lead to altered efficiency of splice-site recognition, resulting in overexpression or down-regulation of certain splice variants, a switch in splice-site usage, or failure to recognize splice sites correctly, resulting in cancer-specific splice forms. At least in some cases, changes in splicing have been shown to play a functionally significant role in tumorigenesis, either by inactivating tumor suppressors or by gain of function of proteins promoting tumor development. Moreover, cancer-specific splicing events may generate novel epitopes that can be recognized by the host's immune system as cancer specific and may serve as targets for immunotherapy. Thus, the identification of cancer-specific splice forms provides a novel source for the discovery of diagnostic or prognostic biomarkers and tumor antigens suitable as targets for therapeutic intervention.

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20156DOI Listing
April 2005
3 Reads

Publication Analysis

Top Keywords

splice forms
12
splice-site selection
8
cancer-specific splice
8
regulatory proteins
8
splicing
7
splice
6
cancer
5
fhit susceptibility
4
recognized host's
4
mdm2 fhit
4
usage failure
4
host's immune
4
example cd44
4
susceptibility cancer
4
cd44 mdm2
4
example brca1
4
splicing defects
4
role tumorigenesis
4
defects inherited
4
generate novel
4

Altmetric Statistics

References

(Supplied by CrossRef)

Agata et al.
Cancer Genet Cytogenet 2003

Aigner et al.
Oncogene 2001

Ali Eldib et al.
Int J Cancer 2004

Barbour et al.
Cancer Res 2003

Barnes et al.
Biochemistry 1996

Bartel et al.
Cancer Cell 2002

Bartel et al.
Mol Cancer Res 2004

Behrends et al.
Int J Cancer 2002

Black et al.
Annu Rev Biochem 2003

Brett et al.
FEBS Lett 2000

Burset et al.
Nucleic Acids Res 2000

Similar Publications